Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InogenINGN -5.13%66 Buyback Yield % is 1.06 as of Aug. 06, 2026. GuruFocus rates INGN with a GF Score™ of 66/100 and a GF Value™ of $6.94 (Fairly Valued). The stock has 3 warning signs investors should review. Among 345 Medical Devices & Instruments companies, Inogen ranks better than 80% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Inogen's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
INGN vs QSI, APYX, QTRX: Buyback Yield % Comparison
For the Medical Devices subindustry, Inogen's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inogen Buyback Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Inogen's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Inogen's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inogen (INGN) has a Buyback Yield % of 1.06 as of Aug. 06, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Inogen and its competitors. According to the industry distribution chart, Inogen ranks #69 out of 345 companies in the Medical Devices & Instruments industry, placing it in the top 20%.
Is Inogen's Buyback Yield % too high?
Inogen's current Buyback Yield % is 1.06. Based on the distribution chart, Inogen ranks #69 out of 345 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Inogen has a GF Score™ of 66/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Inogen's Buyback Yield % compare to QSI and APYX?
According to the Medical Devices & Instruments industry distribution chart, Inogen ranks #69 out of 345 companies for Buyback Yield %. This places Inogen in the top 20% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Devices & Instruments company?
A good Buyback Yield % depends on the Medical Devices & Instruments industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Inogen and its competitors. Inogen's current Buyback Yield % is 1.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inogen stock overvalued right now?
Based on GuruFocus' analysis, Inogen (INGN) is currently considered Fairly Valued. The stock's GF Value™ is $6.94, compared to a current price of $6.55 — trading 5.7% below its estimated fair value. The current Buyback Yield % is 1.06. Inogen's overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Inogen (INGN), the current Buyback Yield % is 1.06 as of Aug. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Inogen (INGN) Overvalued in 2026?
Based on GuruFocus' analysis, Inogen stock appears to be undervalued.
The current stock price of $6.55 is trading 5.7% below its estimated GF Value™ of $6.94.
GuruFocus considers Inogen to be Fairly Valued.
Key valuation signals for INGN:
Buyback Yield %: 1.06
GF Value™: $6.94 vs. price of $6.55 (5.7% below fair value)
No single metric tells the full story. See the INGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Inogen Inc is a medical technology business that focuses on respiratory health. It develops, manufactures, and markets respiratory health products, including portable oxygen concentrators, or POCs, used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions and the Simeox product for airway clearance treatment. In addition, it has started distributing the Inogen Voxi 5 stationary oxygen concentrator as well as the Aurora continuous positive airway pressure, or CPAP, masks in the United States. The company derives revenues from customers through the development, manufacturing, marketing, sales, and rental of respiratory products.
66GF Score
Get the complete analysis for INGN
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INGN has been successfully added to your 
